MALIBU trial – Phase II study of combination ibrutinib and rituximab in untreated marginal zone lymphomas

EMCL-Registry

Creation of a European mantle cell lymphoma registry

SAKK 38/23 LIBERTY

Non-Hodgkin B-cell lymphoma

Recruitment completed

HOVON 127/ SAKK 37/16

Phase III study comparing R-CODOX-M/R-IVAC versus dose-adjusted EPOCH-R (DAEPOCH-R) for patients with newly diagnosed high risk Burkitt lymphoma

Recruitment completed

IELSG-37

A randomized, open-label, multicentre, two-arm phase III comparative study assessing the role of mediastinal radiotherapy after Rituximab containing chemotherapy regimens to patients with newly diagnosed Primary Mediastinal Large B-Cell Lymphoma (PMLBCL).

MorningLyte

MORNINGLYTE: international, multicenter phase III study to evaluate the efficacy and tolerability of mosunetuzumab in combination with lenalidomide compared to standard treatment in patients with previously untreated follicular lymphoma.

NX-5948-301

NX-5948-301 A Phase I study to determine the best dose(s) for the treatment of adult patients with B-cell lymphoma or leukemia who have relapsed and/or have not responded to other treatment with the investigational compound NX-5948, which degrades the enzyme Bruton's tyrosine kinase.

Recruitment completed

SAKK 38/19

SAKK 38/19 Therapy adjustment based on PET/CT and circulating tumor DNA in patients with diffuse large B-cell lymphoma

IELSG-48

Phase 3, interventional, multicentre, open-label, randomized study comparing rituximab plus zanubrutinib to rituximab monotherapy in previously untreated, symptomatic splenic marginal zone lymphoma (RITZ)

CLL18

Comparison of three therapies in patients with previously untreated chronic lymphocytic leukemia (CLL) or small cell lymphocytic lymphoma (SLL)